Featured Articles
DRUG DEVELOPMENT - Using a Novel Deep Cyclic Inhibition Mechanism to Treat Broad Range of RAS-Mutant Cancers
Ben Zeskind, PhD, addresses the question: rather than targeting individual RAS mutations and treating chronically, is it possible to achieve broad therapeutic activity in a way that focuses on malignant cells while minimizing damage to healthy cells?
CLINICAL TRIALS - The Power of AI in Overcoming Patient Diversity Challenges
Isaac Bentwich, PhD, explores why patient diversity is such a challenge for clinical trials, where that pain is often felt the most, some of the regulatory, technological, and industry changes already underway to solve the clinical trial gap, and where AI changes the future of patient diversity.
SUPPLY CHAIN VISIBILITY - New Tracking Technologies Driving Improvements to Reduce Drug Shortages, Expedite Recalls, Protect & Inform Patients
Tracy Nasarenko says new technologies are being leveraged along with industry standards to enable full visibility across the entire supply chain, tracking products all the way from manufacturer to end user.
PHARMACOVIGILANCE AUTOMATION - Improving CRO Efficiency Through Automation
Emmanuel Belabe says many CROs believe they’ve reached a breaking point as they work to keep up with rising case volumes, data complexities, and changing regulations. To combat these pressures, CROs need access to modern pharmacovigilance (PV) automation that promotes flexibility, scalability, efficiency, and cost-effectiveness.
ARTIFICIAL INTELLIGENCE PLATFORM - Advancing Precision Medicine With bfLEAP™: Next Generation AI for Drug Development
Thomas Hazel, PhD, and JT Koffenberger explore the technical architecture and capabilities of bfLEAP, delving into its ML algorithms, proprietary clustering techniques, and visually understandable outputs, examine some of the potential use cases for the platform in drug development, and discuss future developments.
2024 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
FORMULATION FORUM – Nanosuspensions - An Enabling Formulation for Improving Solubility & Bioavailability of Drugs
Jim Huang, PhD, and Shaukat Ali, PhD, focus on the role of excipients and methods for preparation and application of nanosuspensions in injectable, ocular, topical, and oral drug delivery.
EXECUTIVE INTERVIEW - Lonza Small Molecules: Facing Up to the Challenges of Drug Development
Jan Vertommen, Lonza’s Head of Commercial Development (Small Molecules) discusses some of the challenges facing the sector and how his company is looking to address them.
PHARMACEUTICAL GLOBALIZATION - Navigating Opportunities & Obstacles
Jürgen Hönig says rapid globalization of the pharmaceutical industry has created new complexities as companies navigate different regulations and government policies, but there are many reasons for optimism, including harmonization, collaboration, and convergence.
CLOUD COMPUTING - Revolutionizing Antibody Discovery: The Role of Cloud Computing
Suhani Nagpal, PhD, Laura Spector, PhD, and Frank Erasmus, PhD, discuss the role of cloud computing in antibody discovery, its benefits, and its potential applications in the field of biotechnology.
EXCLUSIVE ONLINE CONTENT
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Unicycive Therapeutics, Inc. recently announced the US FDA has granted orphan drug designation (ODD) to UNI-494 for the prevention of Delayed Graft Function (DGF) in kidney….
2019 Analytical Testing in Drug Development eBook - Regulations Help Propel Testing Market
This e-Book showcases the various types of services that leading testing companies offer and how they are helping industry comply with regulations to get their products approved and commercialized.
EXECUTIVE INTERVIEW - Oasmia Pharmaceutical: Commercializing Technologies While Pursuing the US Market
Julian Aleksov, Executive Chairman of Oasmia Pharmaceutical, discusses his company’s efforts to enter the US market, its strategy to increase commercial adoption, and why it believes its underlying drug delivery system technology is significant not only within the oncology sector, but the entire pharmaceutical industry.
LIPOPHILIC SALTS - Opportunities & Applications in Oral Drug Delivery
Hywel Williams, PhD, Annabel Igonin, PhD, David Vodak, PhD, and Hassan Benameur, PhD, believe lipophilic salts are being explored in a number of different areas and one interesting application is their potential to boost API loading in lipid formulations.